The impact of a history of psychotic symptoms on cognitive function in euthymic bipolar patients: a comparison with schizophrenic patients and healthy controls

Sofia Brissos,1 Vasco Videira Dias,2,3 Márcio Gerhardt Soeiro-de-Souza,3 Vicent Balanzá-Martínez,4 Flavio Kapczinski5

1 Centro Hospitalar Psiquiátrico de Lisboa, Lisbon, Lisbon, Portugal; Janssen-Cilag Pharmaceutical, Portugal.
2 Bipolar Disorders Research Program, Hospital Santa Maria, Faculty of Medicine, Universidade de Lisboa, (FMUL), Lisbon, Portugal.
3 Mood Disorders Unit, Institute and Department of Psychiatry (IPq), Hospital das Clínicas, Faculty of Medicine, Universidade de São Paulo (USP), São Paulo, Brazil.
4 Section of Psychiatry, Universitat de València, Valencia, Spain, CIBER en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Valencia, Spain
5 Bipolar Disorder Program and Molecular Psychiatry Unit, Hospital de Clínicas, Universidade Federal do Rio Grande do Sul (UFRGS), INCT Translational Medicine, Porto Alegre, Brazil.

Received on September 23, 2010; accepted on December 22, 2010

Abstract
Background: About two-thirds of patients with bipolar disorder (BD) have a lifetime history of at least one psychotic symptom. Objective: To compare the neurocognitive performance of four groups: BD patients with and without a history of psychotic symptoms (BD HPS+ and BD HPS-, respectively); patients with schizophrenia (SZ); and healthy control (HC) subjects. Method: In this cross-sectional study, 35 stabilized patients with SZ, 79 euthymic (44 HPS+ and 35 HPS-) patients with BD, and 50 HC were administered a comprehensive battery of neuropsychological tests. Results: There was worse neurocognitive functioning in both BD and SZ patients compared to HC. Overall, data from both groups of BD patients did not differ on sociodemographic, clinical, or neurocognitive variables. However, BD HPS+ patients had significantly more negative symptoms, as measured by the Positive and Negative Syndrome Scale (PANSS), and showed a trend toward worse performance on executive functions compared to BD HPS- patients. Moreover, both BD groups had better performance on all neurocognitive tests compared to SZ group. Conclusions: Neurocognitive dysfunction may be more marked in SZ than in BD, yet qualitatively similar. A history of past psychotic symptoms in BD was not associated with more severe cognitive impairment during euthymia. Therefore, BD with psychotic symptoms does not appear to be a distinct neurocognitive phenotype.

©2011 Elsevier Editora Ltda. All rights reserved.
Introduction

The traditional Kraepelinian dichotomy of psychoses as completely distinct entities has been challenged by increasing evidence that bipolar disorder (BD) and schizophrenia (SZ) may share several epidemiological, phenomenological, neurobiological, and genetic characteristics. Cognitive function is no exception, as bipolar patients exhibit neurocognitive deficits in many of the same domains reported in patients with SZ, although to a lesser extent. Of particular concern are premorbid and current intelligence quotient, and perhaps attention, verbal memory, and executive functions.

Cognitive impairments have been reported in nearly all cognitive domains in euthymic BD patients and this is more evident for verbal memory and some executive functions, suggesting potential trait markers and possibly endophenotypes of BD. Nevertheless, some argue that cognitive deficits during euthymia could be partly explained by residual affective symptoms. Other factors such as number and subtype of episodes, duration of illness, age at onset of illness, and number of admissions may also be responsible for the cognitive dysfunction found in BD. However, other clinical factors such as rapid cycling, psychotic features, and comorbidity with other axis I disorders, especially anxiety and substance use disorders, remain to be investigated.

About two-thirds of BD patients have a lifetime history of at least one psychotic symptom. The overlap of SZ and BD occurs more commonly in BD patients with psychotic symptoms, which on genetic grounds has been suggested as a specific subtype of BD, probably more similar to SZ. Moreover, the familial aggregation of psychotic features in BD is a consistent finding. Whether psychotic BD represents a distinct biological subtype should be investigated by using neurobiological correlates of psychosis as external validators. The few existing studies have found differences between psychotic and non-psychotic BD with imaging, as well as physiological measures. The extent to which neurophysiological deficits are unique or overlap across BD type I and SZ is unclear, but some deficits (P50 sensory gating, P300, and others) may represent a common physiological mechanism associated with the vulnerability to psychosis in both disorders. However, research on the impact of psychotic symptoms on cognition has yielded conflicting findings. Some authors have found worse cognitive performance in BD patients with psychotic features than in those without, while others have found no such association.

The aims of this study were twofold: 1) to characterize the overall cognitive profile of a well defined sample of euthymic BD patients with a history of psychotic symptoms (BD HPS+) during mood episodes, and of euthymic BD patients without past psychotic symptoms (BD HPS-), as compared to psychosis in both disorders. However, research on the impact of psychotic symptoms on cognition has yielded conflicting findings. Some authors have found worse cognitive performance in BD patients with psychotic features than in those without, while others have found no such association.

The aims of this study were twofold: 1) to characterize the overall cognitive profile of a well defined sample of euthymic BD patients with a history of psychotic symptoms (BD HPS+) during mood episodes, and of euthymic BD patients without past psychotic symptoms (BD HPS-), as compared to psychosis in both disorders. However, research on the impact of psychotic symptoms on cognition has yielded conflicting findings. Some authors have found worse cognitive performance in BD patients with psychotic features than in those without, while others have found no such association.
to SZ patients while in remission (severity criteria), and a control group of healthy individuals; 2) to discern whether there is a distinct profile of cognitive impairment in euthymic BD HPS+ patients as compared to euthymic BD HPS- patients.

Based on the literature, we hypothesized that: (1) compared with control subjects, all patient groups would be impaired in most cognitive functions; (2) compared with SZ patients, BD patients would have a qualitatively similar, yet quantitatively different cognitive profile; (3) compared with non-psychotic BD patients, the psychotic BD group would be additionally more impaired on at least some executive and verbal learning tasks.

**Method**

**Subjects**

The data reported in the present study are based on the analysis of an ongoing investigation of cognitive functioning in SZ and BD patients. Patients were recruited from Centro Hospitalar Psiquiatrico de Lisboa, from Santarem’s District Hospital, and from the Portuguese Association of Bipolar and Depressive Patients (ADEB from Portuguese). Thirty-five outpatients with SZ, aged 20-62, were diagnosed according to DSM-IV criteria and Depressive Patients (ADEB from Portuguese). Thirty-five patients with an association of conventional antipsychotics, three patients with conventional depots alone. Forty BD patients were treated with antipsychotics alone. On the other hand, all patients with SZ were treated with one (63%) or more antipsychotics; 30 patients with atypical antipsychotics, nine patients with an association of conventional antipsychotics, and three patients with conventional depots alone.

Fifty healthy subjects, age 17-61, recruited by convenience amongst the patients’ acquaintances (excluding first-degree relatives) or from hospital personnel, were included as the control group; healthy subjects were screened for psychiatric disorders by means of clinical interview and with the MINI, and excluded if they met the criteria for any psychiatric disorder. No effort was made to match groups on age, sex, and educational level.

Subjects with previous head trauma or neurological illness, substance abuse/dependence or a course of ECT in the preceding six months were excluded. Two BD patients and one healthy control (HC) were left-handed, and one patient with SZ and one HC were ambidextrous, according to the Edinburgh Inventory.

The study was approved by the local Ethics Committee, and all participants provided prior written informed consent.

**Neuropsychological assessment**

The neurocognitive test battery was directed at the following cognitive domains: attention and mental control (Mental Tracking and Digit Span Forward from the Wechsler Memory Scale [WMS], Bells Test); processing speed (Symbol Digit Modalities Test, and Trail Making Test part A); executive functions (Digit Span backward from the WMS, Stroop Color and Color-Write Tests, Trail Making Test part B, and Towers of Hanoi [ToH], Controlled Oral Word Association [COWA] – Animal Naming, also a test of verbal fluency, Wechsler Intelligence Scale for Adults Revised [WAIS-R] – Comprehension and Similarities sub-tests); and verbal memory (WAIS-R – Information sub-test, WMS – Logical Memory). These are well-established tests of which detailed descriptions exist in standard texts. Both psychopathological and neurocognitive assessments were administered on the same day.

**Statistical analyses**

Comparison of clinical and sociodemographic characteristics between the four groups (HPS+ and BD HPS- patients, SZ patients, and HC) was carried out using ANOVA and χ² test as appropriate. Because the results on the neurocognitive tests are highly correlated, we used one-way analysis of variance, with sex and group as factors, and age, educational level, and subsyndromal mood symptoms (HDRS, YMRS scores) as covariates (ANCOVA) to compare neurocognitive performances between the four groups. When a significant group effect (p < 0.05) was observed, Scheffe Post-Hoc Tests were conducted for significant differences between groups.

To indicate the magnitude of differences in neurocognitive performance between the two groups of BD patients and HC, we calculated Cohen’s d effect sizes (not adjusted for age, educational level, and residual mood symptoms). Performances on neurocognitive tests were also converted to Z-scores (for clarity, negative values express worse performances as compared to control subjects). The two groups of BD patients were also directly compared by Student’s t-test and χ² test. Analyses yielding a p value < 0.05 were considered significant.

**Results**

**Comparison of clinical groups with HC**

The four groups differed significantly in sex, age, educational level, and mood subsyndromal symptoms (Table 1). Significant overall neurocognitive differences between the four groups were found, while there was covariance for the above-mentioned variables (MANCOVA; Pillai’s F = 2.45; p < 0.001).
Scheffé Post-Hoc Test revealed that the SZ group performed significantly worse than HC on all tests; BD HPS+ patients performed significantly worse than HC on 11 out of 17 tests, whereas BD HPS- patients performed significantly worse than HC on nine tests (Table 2; see also Figures 1). No main effect of either sex or a group by sex interaction was detected in any neuropsychological variable (Table 2). The largest effect sizes (Cohen’s $d$) were found in the SZ group, ranging between 0.75 and 2.06 (mean = 1.25), whereas BD patients showed moderate effect sizes, ranging between 0.19 and 1.35 (mean = 0.71) in BD HPS- patients, and between 0.27 and 1.55 (mean = 0.78) for BD HPS+ patients (Table 2).

**Figure 1** Z-scores for 17 neurocognitive test scores achieved by patients with bipolar disorder (with and without history of psychotic symptoms) and patients with schizophrenia, as compared to healthy controls.

![Figure 1: Z-scores for 17 neurocognitive test scores](image)

BD HPS-: Bipolar disorder patients without history of psychotic symptoms; BD HPS+: Bipolar disorder patients with history of psychotic symptoms; COWA: Controlled Oral Word Association; HPS -: without history psychotic symptoms; HPS +: with history of psychotic symptoms; ; SCT: Stroop Color Test; SCWT: Stroop Color-Word Test; SDMT: Symbol Digit Modalities Test; SZ: schizophrenia ToH: Hanoi Towers Test; TMT-A: Trail Making Test part A; TMT-B: Trail Making Test part B; WAIS-R: Wechsler Intelligence Scale for Adults - Revised; WMS: Wechsler Memory Scale. For a better understanding of the magnitude of differences between patient groups and healthy controls, all Z-scores are depicted as negative values. Performance of healthy controls on all tests was converted to Z-score of zero.

**Comparison of the two groups of BD patients vs. SZ patients**

The three patient groups did not differ in age at illness onset or illness duration, but patients with SZ manifested significantly more severe symptoms on all PANSS sub-scales, as compared to both BD groups, and significantly more hospital admissions than the HPS- group (Table 1). Both euthymic BD groups outperformed the SZ group on three timed measures (TMT-A, SCT, and SCWT). Interestingly, a different pattern emerged according to the presence or absence of past psychotic symptoms: the BD HPS+ group performed significantly better than the SZ group on mental tracking and perseverations on the SCWT, whereas the HPS- group did better on SDMT and ToH.

Because medication status differed significantly between the three patient groups regarding lithium, anticonvulsants and antipsychotics (Table 1) we controlled for a potential effect of these medications. All between-groups differences remained, except for Bells test ($F = 1.033$, $p = 0.422$), suggesting that psychotropic medication did not seem to influence neurocognitive differences between the patient groups.

**Comparison of the two groups of BD patients**

BD patients of both groups (HPS+ and HPS-) did not differ significantly regarding number of previous manic or depressive episodes (Table 1), sex, age, educational level, age at illness onset, illness duration, number of hospital admissions, mood symptoms, or type of prescribed medication (data not shown). However, euthymic HPS+ patients with BD had significantly higher scores on the PANSS negative sub-scale ($t = 2.07$, $p = 0.042$).

This variable was used as covariate to better compare overall neurocognitive performance between both BD groups (MANCOVA: Pillai’s $F = 0.97$; $p = 0.52$). ANCOVA revealed that HPS+ patients showed a trend toward a worse performance on one test of executive function, ToH ($F = 2.970$, $p = 0.089$; Cohen’s $d = 0.53$).

Patients with past psychotic symptoms ($n = 79$) had significantly fewer years of education ($t = 2.095$; $p = 0.039$), more admissions ($t = -2.324$; $p = 0.022$), worse global functioning measured by GAF ($t = -2.853$; $p = 0.006$), and higher scores on PANSS positive ($t = -3.862$; $p < 0.001$), PANSS negative ($t = -4.988$; $p < 0.001$), PANSS general ($t = -2.636$; $p = 0.01$), and PANSS total ($t = -3.278$; $p = 0.001$), compared with those without psychotic symptoms ($n = 30$). The former group also showed worse performance on three neurocognitive tests: Information ($t = 2.750$; $p = 0.007$), Symbol Digit ($t = 2.599$; $p = 0.011$), and ToH ($t = -3.315$; $p = 0.001$).

**Discussion**

The results of this cross-sectional study with a well-characterized sample of euthymic patients with BD and remitted patients with SZ, suggest that these diagnoses are associated with cognitive impairment compared to healthy subjects. Although the neurocognitive dysfunction may be quantitatively different in SZ, the changes were qualitatively similar between both diagnostic groups. Nonetheless, we report here similar neurocognitive performance in HPS+ and HPS- patients with BD on all neuropsychological tests, suggesting that past psychotic features in BD do not seem to be associated with a more severe cognitive impairment during euthymia.

As hypothesized, the three patient groups showed overall worse neurocognitive functioning as compared to HC. Patients with SZ presented severe, pervasive cognitive deficits, with many large-effect sizes, whereas patients with BD showed relatively milder and more confined deficits than those of patients with SZ. As previously reported, the performance of both patient groups was similar on several tests, namely those of mental control, language function, visual function, memory function and executive function. Conversely, our
findings with the Stroop Test (executive function) suggest that patients with SZ have a disproportionate slowness and significantly more perseverations in incongruent tasks compared to BD patients. This is typically interpreted as an increased susceptibility to interference and a deficit in inhibition, processes that are actively involved in selective attention.\textsuperscript{31} Taken together, our findings support the hypothesis that neurocognitive deficits in BD are qualitatively similar to those of SZ, but quantitatively less pronounced, raising the question of the specificity of cognitive deficits in SZ.\textsuperscript{31} This pattern of cognitive deficit may represent a common pathway within the two disorders.\textsuperscript{32}

It is possible that at least some of the variance in cognitive functions in the BD groups, and also in the SZ group, may be due to subsyndromal mood symptoms.\textsuperscript{32} However, this possibility was decreased by testing patients while they were in remission and enjoying a period of relative well-being. Since we also controlled for the effects of medication, it seems unlikely that the neurocognitive differences between BD and SZ patients could be explained solely by the levels of subsyndromal symptoms, or treatment regimens.

The proportion of BD patients with lifetime psychotic features in this study (60\%) is very similar to that reported for larger samples.\textsuperscript{23} The two BD groups presented very similar neurocognitive performances, as reflected by trivial to small effect sizes in the majority of tests. This suggests that a prior history of psychotic symptoms may not be associated with a more severe cognitive impairment in BD, which is in line with previous reports.\textsuperscript{19,25} However, a recent meta-analysis concluded that while there is a greater severity of cognitive deficits in BD HPS+, these were modest, and therefore no categorical separation could be drawn between BD HPS+ and HPS- patients.\textsuperscript{27} Discrepant results are probably due to methodological differences, such as the use of small,

**Table 1** Sociodemographic and clinical characteristics of patients with bipolar disorder (with and without history of psychotic symptoms), patients with schizophrenia and healthy controls

<table>
<thead>
<tr>
<th>Neuropsychological variable</th>
<th>BD HPS+ patients (n = 30)</th>
<th>BD HPS- patients (n = 44)</th>
<th>SZ patients (n = 35)</th>
<th>HC patients (n = 50)</th>
<th>ANOVA</th>
<th>Scheffé Post Hoc Test ( a )</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>Mean</td>
<td>SD</td>
<td>n</td>
<td>Mean</td>
<td>SD</td>
<td>n</td>
</tr>
<tr>
<td>Age</td>
<td>37.7</td>
<td>10.77</td>
<td>39.4</td>
<td>11.27</td>
<td>40.0</td>
<td>9.79</td>
</tr>
<tr>
<td>Educational level (years)</td>
<td>11.5</td>
<td>3.98</td>
<td>10.36</td>
<td>4.05</td>
<td>9.0</td>
<td>3.46</td>
</tr>
<tr>
<td>Age at illness onset (years)</td>
<td>26.4</td>
<td>9.65</td>
<td>24.8</td>
<td>8.90</td>
<td>24.6</td>
<td>7.70</td>
</tr>
<tr>
<td>Illness duration (years)</td>
<td>10.9</td>
<td>8.50</td>
<td>14.3</td>
<td>9.12</td>
<td>15.6</td>
<td>9.41</td>
</tr>
<tr>
<td>Number of admissions</td>
<td>1.4</td>
<td>2.41</td>
<td>2.2</td>
<td>2.04</td>
<td>3.0</td>
<td>2.57</td>
</tr>
<tr>
<td>Manic episodes</td>
<td>4.7</td>
<td>4.96</td>
<td>5.6</td>
<td>5.14</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Depressive episodes</td>
<td>6.4</td>
<td>5.45</td>
<td>7.7</td>
<td>7.64</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HDRS score</td>
<td>2.4</td>
<td>2.67</td>
<td>3.1</td>
<td>2.45</td>
<td>3.2</td>
<td>2.48</td>
</tr>
<tr>
<td>YMRS score</td>
<td>0.8</td>
<td>1.49</td>
<td>1.1</td>
<td>1.75</td>
<td>0.3</td>
<td>0.96</td>
</tr>
<tr>
<td>PANSS positive</td>
<td>7.2</td>
<td>0.46</td>
<td>7.8</td>
<td>2.07</td>
<td>9.3</td>
<td>3.42</td>
</tr>
<tr>
<td>PANSS negative</td>
<td>8.4</td>
<td>2.51</td>
<td>9.9</td>
<td>3.91</td>
<td>13.9</td>
<td>3.68</td>
</tr>
<tr>
<td>PANSS general</td>
<td>18.8</td>
<td>3.35</td>
<td>20.3</td>
<td>4.47</td>
<td>24.7</td>
<td>8.36</td>
</tr>
<tr>
<td>PANSS total</td>
<td>34.7</td>
<td>5.96</td>
<td>37.9</td>
<td>9.44</td>
<td>48.0</td>
<td>13.17</td>
</tr>
<tr>
<td>Gender ( b )</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>14</td>
<td>46.7</td>
<td>14</td>
<td>31.8</td>
<td>25</td>
<td>71.4</td>
</tr>
<tr>
<td>Female</td>
<td>16</td>
<td>53.3</td>
<td>30</td>
<td>68.2</td>
<td>10</td>
<td>28.6</td>
</tr>
<tr>
<td>Psychiatric medication ( b )</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lithium</td>
<td>15</td>
<td>50.0</td>
<td>12</td>
<td>27.3</td>
<td>2</td>
<td>5.7</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>21</td>
<td>70.0</td>
<td>32</td>
<td>72.7</td>
<td>7</td>
<td>20.0</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>16</td>
<td>53.3</td>
<td>29</td>
<td>65.9</td>
<td>35</td>
<td>100.0</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>13</td>
<td>43.3</td>
<td>14</td>
<td>31.8</td>
<td>8</td>
<td>22.9</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>11</td>
<td>36.7</td>
<td>13</td>
<td>29.5</td>
<td>15</td>
<td>42.9</td>
</tr>
</tbody>
</table>

Significance level \( p < 0.05 \).

\( a \) 1 = Bipolar patients without history of psychotic symptoms; 2 = Bipolar patients with history of psychotic symptoms; 3 = Schizophrenia patients; 4 = Healthy control subjects

\( b \) Fisher’s exact test

SZ: schizophrenia; BD: bipolar disorder; HC: healthy controls; HPS+: with history of psychotic symptoms; HPS-: without history of psychotic symptoms; PANSS: positive and negative syndrome scale.
Table 2 Neuropsychological variables of patients with bipolar disorder (with and without history of psychotic symptoms), patients with schizophrenia and healthy controls

<table>
<thead>
<tr>
<th>Neuropsychological variable</th>
<th>BD HPS- patients (n = 30)</th>
<th>BD HPS+ patients (n = 44)</th>
<th>SZ patients (n = 35)</th>
<th>HC (n = 50)</th>
<th>ANCOVA a</th>
<th>Scheffe Post Hoc Test b</th>
<th>Effect sizes Cohen’s d</th>
<th>F</th>
<th>p</th>
<th>1 vs 2 vs 3 vs 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attention and mental control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental tracking</td>
<td>5.8</td>
<td>2.51</td>
<td>6.0</td>
<td>2.26</td>
<td>4.5</td>
<td>2.19</td>
<td>7.3</td>
<td>1.89</td>
<td>12.372 &lt; 0.001</td>
<td>1 &lt; 4, 2 &lt; 3, 4 &lt; 4</td>
</tr>
<tr>
<td>Digit span (WMS)</td>
<td>8.5</td>
<td>1.61</td>
<td>8.3</td>
<td>1.96</td>
<td>7.9</td>
<td>1.90</td>
<td>10.5</td>
<td>2.25</td>
<td>16.155 &lt; 0.001</td>
<td>1 &lt; 4, 2.3 &lt; 4</td>
</tr>
<tr>
<td>Bells Test (omissions)</td>
<td>2.7</td>
<td>3.47</td>
<td>3.4</td>
<td>4.16</td>
<td>3.6</td>
<td>4.61</td>
<td>4.1</td>
<td>2.00</td>
<td>3.166 0.002</td>
<td>2.3 &lt; 4</td>
</tr>
<tr>
<td>Processing speed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDMT</td>
<td>42.7</td>
<td>12.80</td>
<td>38.6</td>
<td>15.10</td>
<td>30.6</td>
<td>11.71</td>
<td>56.4</td>
<td>14.82</td>
<td>39.532 &lt; 0.001</td>
<td>1 &lt; 3, 4, 2.3 &lt; 4</td>
</tr>
<tr>
<td>TMT-A (sec)</td>
<td>55.3</td>
<td>36.47</td>
<td>55.0</td>
<td>25.95</td>
<td>78.0</td>
<td>50.76</td>
<td>38.0</td>
<td>15.34</td>
<td>10.556 &lt; 0.001</td>
<td>1.2 &lt; 3, 3 &lt; 4</td>
</tr>
<tr>
<td>Executive functions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCWT (sec)</td>
<td>62.0</td>
<td>23.86</td>
<td>62.5</td>
<td>16.18</td>
<td>80.4</td>
<td>27.87</td>
<td>58.5</td>
<td>13.69</td>
<td>7.893 &lt; 0.001</td>
<td>1.2 &lt; 3, 3 &lt; 4</td>
</tr>
<tr>
<td>SCWT (perseverations)</td>
<td>0.7</td>
<td>1.64</td>
<td>0.6</td>
<td>1.23</td>
<td>1.7</td>
<td>2.04</td>
<td>0.3</td>
<td>0.77</td>
<td>5.786 &lt; 0.001</td>
<td>2 &lt; 3, 3 &lt; 4</td>
</tr>
<tr>
<td>SCT (sec)</td>
<td>156.6</td>
<td>44.84</td>
<td>161.9</td>
<td>57.91</td>
<td>201.3</td>
<td>86.17</td>
<td>122.4</td>
<td>32.99</td>
<td>12.652 &lt; 0.001</td>
<td>1.2 &lt; 3, 2.3 &lt; 4</td>
</tr>
<tr>
<td>SCT (perseverations)</td>
<td>5.6</td>
<td>9.38</td>
<td>5.6</td>
<td>5.67</td>
<td>11.2</td>
<td>15.39</td>
<td>2.4</td>
<td>2.72</td>
<td>7.196 &lt; 0.001</td>
<td>3 &lt; 4</td>
</tr>
<tr>
<td>TMT-B (sec)</td>
<td>155.4</td>
<td>128.83</td>
<td>175.7</td>
<td>124.32</td>
<td>224.5</td>
<td>129.92</td>
<td>84.6</td>
<td>35.83</td>
<td>17.215 &lt; 0.001</td>
<td>1 &lt; 4, 2.3 &lt; 4</td>
</tr>
<tr>
<td>ToH (moves)</td>
<td>18.1</td>
<td>7.92</td>
<td>22.9</td>
<td>9.85</td>
<td>88.0</td>
<td>10.11</td>
<td>12.5</td>
<td>7.17</td>
<td>15.338 &lt; 0.001</td>
<td>1 &lt; 3, 4, 2.3 &lt; 4</td>
</tr>
<tr>
<td>COWA</td>
<td>16.5</td>
<td>6.66</td>
<td>15.6</td>
<td>4.36</td>
<td>13.9</td>
<td>4.15</td>
<td>18.2</td>
<td>4.70</td>
<td>9.401 &lt; 0.001</td>
<td>3 &lt; 4</td>
</tr>
<tr>
<td>Comprehension (WAIS-R)</td>
<td>14.2</td>
<td>6.78</td>
<td>13.0</td>
<td>6.24</td>
<td>10.2</td>
<td>7.30</td>
<td>19.4</td>
<td>6.60</td>
<td>26.029 &lt; 0.001</td>
<td>1 &lt; 4, 2.3 &lt; 4</td>
</tr>
<tr>
<td>Similarities (WAIS-R)</td>
<td>9.6</td>
<td>5.39</td>
<td>9.2</td>
<td>6.39</td>
<td>6.4</td>
<td>4.93</td>
<td>15.5</td>
<td>7.04</td>
<td>52.128 &lt; 0.001</td>
<td>1 &lt; 4, 2.3 &lt; 4</td>
</tr>
<tr>
<td>Verbal memory function</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Information (WAIS-R)</td>
<td>19.0</td>
<td>3.59</td>
<td>17.4</td>
<td>6.41</td>
<td>15.0</td>
<td>6.39</td>
<td>20.7</td>
<td>5.36</td>
<td>17.385 &lt; 0.001</td>
<td>1 &lt; 4, 2.3 &lt; 4</td>
</tr>
<tr>
<td>Logical memory (WMS)</td>
<td>5.8</td>
<td>1.90</td>
<td>5.2</td>
<td>2.25</td>
<td>4.4</td>
<td>1.51</td>
<td>9.0</td>
<td>2.62</td>
<td>30.916 &lt; 0.001</td>
<td>1 &lt; 4, 2.3 &lt; 4</td>
</tr>
</tbody>
</table>

a Analyses of variance (ANCOVA) with sex, age, educational level, HDRS, and YMRS as covariates.
b 1 = Bipolar patients without history of psychotic symptoms; 2 = Bipolar patients with history of psychotic symptoms; 3 = Schizophrenia patients; 4 = Healthy control subjects;

BD: bipolar disorder; COWA: Controlled Oral Word Association; HC: healthy controls; HPS -: without history of psychotic symptoms; HPS +: with history of psychotic symptoms; SCT: Stroop Color Test; SCWT: Stroop Color-Write Test; SDMT: Symbol Digit Modalities Test; SZ: schizophrenia; ToH: Hanoi Towers Test; TMT-A: Trail Making Test part A; TMT-B: Trail Making Test part B; WAIS-R: Wechsler Intelligence Scale for Adults - Revised; WMS: Wechsler Memory Scale.

The sign (+) indicates better performance, and not actual scores on the tests.

heterogeneous samples. It is noteworthy that most previous research assessed non-euthymic patients, with acute symptoms possibly confounding the results.

Studying a sample of true euthymic BD patients may reduce the additional effect of past psychotic symptoms in neurocognitive test performance. Four studies have compared the neurocognitive function of psychotic and non-psychotic euthymic BD patients to those of HC11,16,19,25 and of healthy relatives.26 Of these, three studies did find some selective differences in neurocognitive performance, which their authors attributed to the presence of past psychotic features. It has been suggested that psychotic BD might represent a distinct subgroup of BD with impairments in three working memory/executive tasks.11 Moreover, differences were found in the number of categories of the Wisconsin Card Sorting Test (WCST), suggesting that deficits in cognitive flexibility could be a trait marker of psychotic features in BD.16 More recently, Martinez-Arán et al. (2008) found greater impairment on verbal memory assessed with a list-learning task in BD HPS+ patients as compared to both HC and BD HPS- patients.19

Although our findings are in contrast to previous studies, a closer inspection of data reveals that the proportion of impaired neuropsychological variables were 1/17,16 5/16 (all from the same list-learning test),26 1/19 (after controlling for treatment and mood symptoms).11 Furthermore, we did not use any of the tests in which differences were reported in the above-mentioned studies. Taken together, the literature suggests that cognitive function may be more similar than different during euthymia, independently of lifetime psychotic symptoms.

Conversely, only one of four studies, which similarly compared psychotic and non-psychotic patients with BD to those with SZ, reached a negative finding. Szoke et al. (2008) compared the cognitive performances of subjects with SZ, BD HPS+, BD HPS-, schizoaffective disorder, and HC using WCST and TMT.25 Psychotic and non-psychotic BD patients showed similar results and both BD groups outperformed the SZ group on the WCST. Although all subjects were euthymic, they were assessed just before discharge and clinical symptoms were not controlled. Thus, as the authors acknowledge, the influence of symptoms could not be completely ruled out. The
The impact of a history of psychotic symptoms on cognitive function in euthymic bipolar patients: a comparison with schizophrenic patients and healthy controls

The use of only two executive tasks instead of a comprehensive neuropsychological battery further limited this comparison. Therefore, ours is the first study with a large sample of well-defined euthymic BD patients reporting a similar performance on a broad range of cognitive tests, regardless of a history of psychosis over their lifetime, and results suggest that if there is an effect of psychosis on neurocognitive performance, it is not very strong.

Our two BD groups were similar in demographic and clinical terms, as well as in medication usage. This latter issue is important because cognitive dysfunction in BD has also been associated with antipsychotic medication rather than with psychotic symptoms by some investigators, but not others. In our study, psychotropic medication did not seem to influence neurocognitive differences between patients’ groups. Lithium and most anticonvulsants may impair associative fluency, verbal memory, short- and long-term memory, and processing speed, although apparently in a reversible way, and the more beneficial cognitive effects seen with atypical antipsychotics in SZ patients have not been sufficiently proven in BD patients. Therefore, the possibility that some treatments may negatively impact cognitive function cannot be excluded, especially with high doses or with combination therapy. Interestingly, BD HPS+ patients presented significantly more negative symptoms than their non-psychotic counterparts, and cognitive similarities remained after covariation for that difference. The relationship between negative symptoms and cognition during euthymia has not been well studied, although negative symptoms have been associated with poorer cognitive functioning in remitted BD patients. Moreover, significant associations have been found in euthymic patients with variables more related to SZ, such as family history of SZ and a history of mood-incongruent psychotic features, and factors which are correlated with negative symptoms in SZ, such as a history of obstetric complications, the level of premorbid functioning, and younger age at illness onset. Finally, SZ patients with predominantly negative symptoms may have more extensive neurocognitive involvement and worse neuropsychological performance than euthymic BD patients.

It should be pointed out that the neuropsychological tests frequently used in studies in subjects with psychiatric disorders were designed to evaluate patients with focal brain damage, and may not be sensitive enough to detect the subtle putative neurocognitive differences between psychotic and non-psychotic BD patients. With this in mind, to better evaluate psychiatric disorders such as BD, the use of experimental tasks in which single cognitive constructs are manipulated has been proposed. This may also explain the trend to poorer performance that our BD HPS+ patients showed on the ToH. Moreover, performance on this task was significantly correlated with past psychotic symptoms among the BD sample. The ToH is generally regarded as a measure of executive functioning, requiring processing mediated by the frontal cortex, and may be more sensitive in detecting subtle lesions that psychotic symptoms might produce in prefrontal circuits. This suggests that psychotic symptoms may have underlying neural correlates that are, at least partially, independent of those associated with non-psychotic BD.

History of psychotic symptoms over patients’ lifetime would be less relevant than the BD phenotype and most, if not all, cognitive dysfunctions might stem from the disease process itself. It is possible that certain clinical factors, such as the number and duration of mood episodes, illness duration, number of hospitalizations, and co-morbid conditions, would negatively influence cognition. In this sense, cognitive impairment could be the result of the non-linear action of factors, such as inherited vulnerability, allostatic load, sensitization/kindling and coping. Psychotic symptoms in BD have been associated with longer recovery periods from mood episodes and more manic episodes. In our sample, the number of admissions was associated with more psychotic features, which corroborates the previous data. Number of hospitalizations is probably a proxy measure of illness severity, and as such, may suggest a direct relationship between illness severity and neurocognitive functioning. Nevertheless, it remains unclear whether psychotic BD conveys a more severe prognosis.

Finally, our results do not support the idea that psychotic BD is closer to the SZ spectrum disorders, at least on the basis of neurocognitive findings. However, much more research is needed and the search for valid endophenotypes of psychotic BD is thought to have relevant implications for diagnosis, prognosis, and treatment.

Our findings should be considered cautiously due to several limitations. First, our sample comprised a larger proportion of male in the SZ group and sex differences in neurocognitive function have been demonstrated. However, sex was used as a covariate in all comparisons and there was no significant interaction between sex and diagnostic group. Second, psychotic symptoms were narrowly defined, capturing only hallucinations and/or delusions, and were not assessed by means of structured instruments. Because disorganized thought or behaviour was not considered, some BD patients may have been misclassified as non-psychotic. Nevertheless, our definition is consistent with that in the previous literature. Third, low premorbid intellectual functioning has been found in patients with SZ but not in non-psychotic BD patients although we did not control for this factor in our study, we controlled for the educational level, which correlates highly with premorbid IQ. Finally, the study was cross-sectional, and all patients except one were medicated, compared to none of the HC.

Conversely, the strengths of this study include the relatively large sample of BD patients, inclusion of homogeneous groups, with assessment of a broad range of psychopathological symptoms and clearly defined criteria for euthymia, and use of an extensive neurocognitive test battery administered to all participants by the same investigator.

Conclusions

To our knowledge, this is the first study to compare directly HPS+ and HPS- euthymic BD type I patients and SZ patients with severity remission criteria to HC with a comprehensive neuropsychological assessment. Our findings suggest that the patterns of neurocognitive dysfunction may be quantitatively more marked in SZ than in euthymic BD patients, but seem qualitatively similar in both disorders. Our results also suggest that past psychotic features in BD are not associated with a more severe cognitive impairment during euthymia, and cast
doubt on whether psychotic BD is a distinct phenotype, from a neurocognitive perspective. The neurocognitive performance of psychotic BD patients does not seem to be closer to that of SZ patients, questioning the role of psychotic symptoms in favour of a continuum between mood disorders and the schizophrenic spectrum. The performances in cognitive functioning of BD HPS+ patients occupying a position more or less intermediate between those of BD HPS- patients and SZ patients may be attributed to other clinical variables, possibly to the presence of negative symptoms which deserve further investigation.

Acknowledgements

We wish to thank Dr. David Glahn and Dr. Trevor Young for the critical reading of the manuscript.

Disclosures

Sofía Brissos


Vasco Videira Dias

Employment: Hospital Santa Maria, Faculty of Medicine, Universidade de Lisboa, IFMUL, Lisbon, Portugal; Consultant for Angelini Pharmaceuticals.

Research grant: Roche. Other research grant or medical continuous education: Sanofi-Aventis, AstraZeneca, Bristol-Myers-Squibb, Janssen-Cilag, and Lundbeck.

Mário Gerhardt Soeiro de Souza

Employment: Hospital das Clínicas, Faculty of Medicine, Universidade de São Paulo (USP), Brazil; Investigator in ongoing clinical trial sponsored by AstraZeneca. Other research grant or medical continuous education: Lundbeck and Bristol-Myers-Squibb (BMS). Speaker’s honoraria: Lundbeck and BMS.

Vincent Balanzá-Martínez

Research grant: Universitat de València, Valencia; Investigator in ongoing clinical trial sponsored by AstraZeneca. Other research grant or medical continuous education: AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, Janssen-Cilag, and Pfizer.

Flávio Kapczinski

Employment: Hospital de Clínicas, Universidade Federal do Rio Grande do Sul (UFRGS), INCT Translational Medicine, Brazil; NARSAD Independent Investigator. Research grant: Stanley Research Center, CNPq, CAPES, FAPESP. Speaker’s honoraria: Lilly, AstraZeneca, Jansen, Servier, and Roche.

* Modest
** Significant
*** Significant: Amounts given to the author’s institution or to a colleague for research in which the author has participated, not directly to the author.

The authors declare no potential conflicts of interest relative to the contents of this paper.

References


